BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24410339)

  • 1. Hitting the bull's eye: targeting HMGA1 in cancer stem cells.
    Yanagisawa BL; Resar LM
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):23-30. PubMed ID: 24410339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells.
    Shah SN; Cope L; Poh W; Belton A; Roy S; Talbot CC; Sukumar S; Huso DL; Resar LM
    PLoS One; 2013; 8(5):e63419. PubMed ID: 23658826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p53 levels.
    Puca F; Colamaio M; Federico A; Gemei M; Tosti N; Bastos AU; Del Vecchio L; Pece S; Battista S; Fusco A
    Oncotarget; 2014 May; 5(10):3234-45. PubMed ID: 24833610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High mobility group A1 and cancer: potential biomarker and therapeutic target.
    Shah SN; Resar LM
    Histol Histopathol; 2012 May; 27(5):567-79. PubMed ID: 22419021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
    Wei F; Zhang T; Deng SC; Wei JC; Yang P; Wang Q; Chen ZP; Li WL; Chen HC; Hu H; Cao J
    Cancer Lett; 2019 May; 450():1-13. PubMed ID: 30776481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons from the Crypt: HMGA1-Amping up Wnt for Stem Cells and Tumor Progression.
    Resar L; Chia L; Xian L
    Cancer Res; 2018 Apr; 78(8):1890-1897. PubMed ID: 29618461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells.
    Kim DK; Seo EJ; Choi EJ; Lee SI; Kwon YW; Jang IH; Kim SC; Kim KH; Suh DS; Seong-Jang K; Lee SC; Kim JH
    Exp Mol Med; 2016 Aug; 48(8):e255. PubMed ID: 27561949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.
    Sumter TF; Xian L; Huso T; Koo M; Chang YT; Almasri TN; Chia L; Inglis C; Reid D; Resar LM
    Curr Mol Med; 2016; 16(4):353-93. PubMed ID: 26980699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The high mobility group A1 molecular switch: turning on cancer - can we turn it off?
    Huso TH; Resar LM
    Expert Opin Ther Targets; 2014 May; 18(5):541-53. PubMed ID: 24684280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential.
    Wang L; Zhang J; Xia M; Liu C; Zu X; Zhong J
    Int J Biol Sci; 2022; 18(11):4414-4431. PubMed ID: 35864955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness.
    Pegoraro S; Ros G; Piazza S; Sommaggio R; Ciani Y; Rosato A; Sgarra R; Del Sal G; Manfioletti G
    Oncotarget; 2013 Aug; 4(8):1293-308. PubMed ID: 23945276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location!
    Pujals M; Resar L; Villanueva J
    Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High mobility group A1 protein modulates autophagy in cancer cells.
    Conte A; Paladino S; Bianco G; Fasano D; Gerlini R; Tornincasa M; Renna M; Fusco A; Tramontano D; Pierantoni GM
    Cell Death Differ; 2017 Nov; 24(11):1948-1962. PubMed ID: 28777374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer stem cells: a new framework for the design of tumor therapies.
    Garvalov BK; Acker T
    J Mol Med (Berl); 2011 Feb; 89(2):95-107. PubMed ID: 20890588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells.
    Colamaio M; Tosti N; Puca F; Mari A; Gattordo R; Kuzay Y; Federico A; Pepe A; Sarnataro D; Ragozzino E; Raia M; Hirata H; Gemei M; Mimori K; Del Vecchio L; Battista S; Fusco A
    Expert Opin Ther Targets; 2016 Oct; 20(10):1169-79. PubMed ID: 27486901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast Cancer.
    Maurizio E; Wiśniewski JR; Ciani Y; Amato A; Arnoldo L; Penzo C; Pegoraro S; Giancotti V; Zambelli A; Piazza S; Manfioletti G; Sgarra R
    Mol Cell Proteomics; 2016 Jan; 15(1):109-23. PubMed ID: 26527623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in Cancer Stem Cell Targeted Therapy.
    Akbulut H; Babahan C; Abgarmi SA; Ocal M; Besler M
    Crit Rev Oncog; 2019; 24(1):1-20. PubMed ID: 31679215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMGA1 exacerbates tumor growth through regulating the cell cycle and accelerates migration/invasion via targeting miR-221/222 in cervical cancer.
    Fu F; Wang T; Wu Z; Feng Y; Wang W; Zhou S; Ma X; Wang S
    Cell Death Dis; 2018 May; 9(6):594. PubMed ID: 29789601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells.
    Zhang Y; Ma T; Yang S; Xia M; Xu J; An H; Yang Y; Li S
    Mol Cell Biochem; 2011 Nov; 357(1-2):363-71. PubMed ID: 21656127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells.
    Treff NR; Dement GA; Adair JE; Britt RL; Nie R; Shima JE; Taylor WE; Reeves R
    Oncogene; 2004 Nov; 23(52):8557-62. PubMed ID: 15378028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.